When healthy adults are given a drug called acipimox to temporarily block fat breakdown, their blood sugar and insulin levels after eating drop by about 12% and 28%, respectively, but the liver's production of glucose remains unchanged.

We analyzed one assertion on acipimox and its effect on postprandial glucose and insulin in healthy adults. What we’ve found so far is that when healthy adults take acipimox — a drug that temporarily blocks fat breakdown — their blood sugar levels after eating drop by about 12%, and insulin levels drop by about 28% [1]. At the same time, the liver’s production of glucose does not appear to change under these conditions [1]. This single assertion suggests that blocking fat breakdown with acipimox may influence how the body handles sugar and insulin after a meal. The drop in insulin could mean the body needs less of it to manage the same amount of glucose, but we don’t know why this happens or whether it’s due to changes in muscle uptake, fat tissue signaling, or other factors. We also don’t know if this effect lasts beyond a single meal or applies to people with different diets, activity levels, or metabolic health. There is no evidence in our review that contradicts this finding, but we only have one assertion to work with — and it doesn’t include details like sample size, study duration, or how the drug was administered. Without more studies, we can’t say whether this effect is consistent, meaningful in the long term, or safe to replicate outside of a controlled setting. For now, the evidence we’ve reviewed leans toward the idea that acipimox lowers post-meal glucose and insulin in healthy adults, but we don’t yet understand how or why. If you’re considering any supplement or drug to manage blood sugar, it’s best to talk with a healthcare provider — what works in a lab setting doesn’t always translate to real life.